Cancer and Oncology Research

Biography

Prof. A.R. Thierry has a strong background in synthetic DNA complex formation, notably its use for the in vivo gene therapy he developed for cancer and HIV at the Georgetown University and the US National Cancer Institute, with Dr RC Gallo. He was the principal founder of MedinCell SA (Jacou, France) devoted initially to the development of drug delivery system, in particular for nucleic acids. His area of expertise is particularly applicable to research which focusses on the diagnostic capacity of circulating nucleic acids (cirDNA), and on the development of methods which support personalized medicine. His team has developed an modèle préclinique model to specifically quantify the different origins of cirDNA, and has demonstrated the importance of short cirDNA fragment detection for high specificity and sensitivity in cirDNA analysis.That observation enabled dominant IP and the design of the IntPlex test. At the Inst. Cancer Res. of Montpellier (INSERM), France, A.R. Thierry coordinated the first prospective blinded multicenter study to offer clinical validation of plasma analysis which detects mutations in cancer patients. Recently, his team was the first to demonstrate the clinical utility of using cirDNA analysis for mCRC patients

Research Interest

DNA complex formation,ivo gene therapy he developed for cancer and HIV